Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Clinical Study of Allogenic CD123-CAR-NK Cells (JD023 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia

NCT05574608 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.

NCT NCT05574608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05574608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Clinical Study of Allogenic CD123-CAR-NK Cells (JD023 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia
Lead sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2022
Completion date
October 30, 2024
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia recurrent, acute myeloid leukemia refractory